VSTM: Advancing RAS/MAPK therapies with pivotal trials and new data to expand cancer treatment options
The session highlighted progress in commercial and clinical programs for RAS/MAPK-driven therapies, including a strong launch for the CO-PACK in ovarian cancer and advancing VS-7375 in multiple tumor types. Key upcoming data and confirmatory trials aim to expand indications and demonstrate best-in…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.